RxDoctor Payments Data

Karla Querbes, MD

Internal Medicine · Shreveport, LANPI 1194756437

Payments from drug & device makers

$2,075in general payments, 2019–2025

Across 127 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$420
  • Lilly USA, LLC$235
  • AstraZeneca$201
  • Abbott$187
  • Novo Nordisk$175
  • Johnson & Johnson$115
  • plus $741 from 21 others

What the payments were for

  • Food & beverage$2,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,075 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$64,909
Medicare patients
259
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$74,322
LinzessLinaclotide44$41,799
EliquisApixaban33$30,562
EntrestoSacubitril/Valsartan32$28,365
MounjaroTirzepatide23$28,286
TrulicityDulaglutide24$25,483
JanuviaSitagliptin Phosphate15$22,082
FarxigaDapagliflozin Propanediol11$17,607
JanumetSitagliptin Phos/Metformin Hcl14$13,460
JardianceEmpagliflozin12$13,048
MyrbetriqMirabegron23$11,949
Tresiba Flextouch U-100Insulin Degludec11$8,805
Dexlansoprazole DrDexlansoprazole21$4,918
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$4,770
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$175$74,32259 claims
Lilly USA, LLCMounjaro, Trulicity$235$53,76947 claims
AbbVieLinzess$51$41,79944 claims
MerckJanuvia, Janumet$30$35,54229 claims
PfizerEliquis$420$30,56233 claims
AstraZenecaFarxiga$201$17,60711 claims
Boehringer IngelheimJardiance$44$13,04812 claims
Astellas Pharma US IncMyrbetriq$33$11,94923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →